

Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Growth 2023-2029

<https://marketpublishers.com/r/G97A0D9BDED2EN.html>

Date: February 2023

Pages: 93

Price: US\$ 3,660.00 (Single User License)

ID: G97A0D9BDED2EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The immunoglobulin combination was separated and extracted from normal human plasma by the low-temperature ethanol method, and refined through further processing and virus inactivation steps. This product is a complete, unmodified natural IgG antibody with a purity of up to 98%. It contains no preservatives and antibiotics and is intended for intravenous infusion. Compared with intramuscular gamma globulin, it has a faster effect and a significant effect. advantage.

LPI (LP Information)' newest research report, the "Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Industry Forecast" looks at past sales and reviews total world Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) sales for 2023 through 2029. With Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) industry.

This Insight Report provides a comprehensive analysis of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in

an accelerating global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19).

The global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) players cover Boya-Bio, Beijing Tiantan Biological Products, Hualan Bio, Guangdong Shuaglin Bio-pharmacy, Weiguang Biological, Sinopharm, Shanghai RAAS, CTBB and Nanyue Biopharming, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

1g/20ml

1.25g/25ml

2.5g/50ml

5g/100ml

10g/200ml

Segmentation by application

Hospital

Clinic

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Boya-Bio

Beijing Tiantan Biological Products

Hualan Bio

Guangdong Shuagnlin Bio-pharmacy

Weiguang Biological

Sinopharm

Shanghai RAAS

CTBB

Nanyue Biopharming

Key Questions Addressed in this Report

What is the 10-year outlook for the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market?

What factors are driving Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) market opportunities vary by end market size?

How does Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

2.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)
Annual Sales 2018-2029

2.1.2 World Current & Future Analysis for Human Immunoglobulin (pH4) for
Intravenous Injection (COVID-19) by Geographic Region, 2018, 2022 & 2029

2.1.3 World Current & Future Analysis for Human Immunoglobulin (pH4) for
Intravenous Injection (COVID-19) by Country/Region, 2018, 2022 & 2029

2.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Type

2.2.1 1g/20ml

2.2.2 1.25g/25ml

2.2.3 2.5g/50ml

2.2.4 5g/100ml

2.2.5 10g/200ml

2.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type

2.3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales
Market Share by Type (2018-2023)

2.3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)
Revenue and Market Share by Type (2018-2023)

2.3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sale
Price by Type (2018-2023)

2.4 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Segment by Application

2.4.1 Hospital

2.4.2 Clinic

2.4.3 Others

2.5 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application

2.5.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sale Market Share by Application (2018-2023)

2.5.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue and Market Share by Application (2018-2023)

2.5.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sale Price by Application (2018-2023)

3 GLOBAL HUMAN IMMUNOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION (COVID-19) BY COMPANY

3.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Breakdown Data by Company

3.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Annual Sales by Company (2018-2023)

3.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Company (2018-2023)

3.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Annual Revenue by Company (2018-2023)

3.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Company (2018-2023)

3.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Company (2018-2023)

3.3 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sale Price by Company

3.4 Key Manufacturers Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Location Distribution

3.4.2 Players Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR HUMAN IMMUNOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION (COVID-19) BY GEOGRAPHIC REGION

4.1 World Historic Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Geographic Region (2018-2023)

4.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size by Country/Region (2018-2023)

4.2.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Annual Sales by Country/Region (2018-2023)

4.2.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Annual Revenue by Country/Region (2018-2023)

4.3 Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth

4.4 APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth

4.5 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth

4.6 Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth

5 AMERICAS

5.1 Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country

5.1.1 Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2018-2023)

5.1.2 Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2018-2023)

5.2 Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type

5.3 Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region

6.1.1 APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2018-2023)

6.1.2 APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Region (2018-2023)

6.2 APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type

6.3 APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Country

7.1.1 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2018-2023)

7.1.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2018-2023)

7.2 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type

7.3 Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) by Country

8.1.1 Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2018-2023)

8.1.2 Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2018-2023)

8.2 Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type

8.3 Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

10.3 Manufacturing Process Analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

10.4 Industry Chain Structure of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

- 11.1.1 Direct Channels
- 11.1.2 Indirect Channels
- 11.2 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors
- 11.3 Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customer

12 WORLD FORECAST REVIEW FOR HUMAN IMMUNOGLOBULIN (PH4) FOR INTRAVENOUS INJECTION (COVID-19) BY GEOGRAPHIC REGION

- 12.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Size Forecast by Region
 - 12.1.1 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Forecast by Region (2024-2029)
 - 12.1.2 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Forecast by Type
- 12.7 Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Boya-Bio
 - 13.1.1 Boya-Bio Company Information
 - 13.1.2 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications
 - 13.1.3 Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 Boya-Bio Main Business Overview
 - 13.1.5 Boya-Bio Latest Developments
- 13.2 Beijing Tiantan Biological Products
 - 13.2.1 Beijing Tiantan Biological Products Company Information
 - 13.2.2 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications
 - 13.2.3 Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2018-2023)

- 13.2.4 Beijing Tiantan Biological Products Main Business Overview
- 13.2.5 Beijing Tiantan Biological Products Latest Developments
- 13.3 Hualan Bio
 - 13.3.1 Hualan Bio Company Information
 - 13.3.2 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications
 - 13.3.3 Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.3.4 Hualan Bio Main Business Overview
 - 13.3.5 Hualan Bio Latest Developments
- 13.4 Guangdong Shuagnlin Bio-pharmacy
 - 13.4.1 Guangdong Shuagnlin Bio-pharmacy Company Information
 - 13.4.2 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications
 - 13.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.4.4 Guangdong Shuagnlin Bio-pharmacy Main Business Overview
 - 13.4.5 Guangdong Shuagnlin Bio-pharmacy Latest Developments
- 13.5 Weiguang Biological
 - 13.5.1 Weiguang Biological Company Information
 - 13.5.2 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications
 - 13.5.3 Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.5.4 Weiguang Biological Main Business Overview
 - 13.5.5 Weiguang Biological Latest Developments
- 13.6 Sinopharm
 - 13.6.1 Sinopharm Company Information
 - 13.6.2 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications
 - 13.6.3 Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.6.4 Sinopharm Main Business Overview
 - 13.6.5 Sinopharm Latest Developments
- 13.7 Shanghai RAAS
 - 13.7.1 Shanghai RAAS Company Information
 - 13.7.2 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications
 - 13.7.3 Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection

(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Shanghai RAAS Main Business Overview

13.7.5 Shanghai RAAS Latest Developments

13.8 CTBB

13.8.1 CTBB Company Information

13.8.2 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Product Portfolios and Specifications

13.8.3 CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 CTBB Main Business Overview

13.8.5 CTBB Latest Developments

13.9 Nanyue Biopharming

13.9.1 Nanyue Biopharming Company Information

13.9.2 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection
(COVID-19) Product Portfolios and Specifications

13.9.3 Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection
(COVID-19) Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 Nanyue Biopharming Main Business Overview

13.9.5 Nanyue Biopharming Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)
- Table 2. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)
- Table 3. Major Players of 1g/20ml
- Table 4. Major Players of 1.25g/25ml
- Table 5. Major Players of 2.5g/50ml
- Table 6. Major Players of 5g/100ml
- Table 7. Major Players of 10g/200ml
- Table 8. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2018-2023) & (K Units)
- Table 9. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2018-2023)
- Table 10. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Type (2018-2023) & (\$ million)
- Table 11. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2018-2023)
- Table 12. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sale Price by Type (2018-2023) & (US\$/Unit)
- Table 13. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2018-2023) & (K Units)
- Table 14. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2018-2023)
- Table 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Application (2018-2023)
- Table 16. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application (2018-2023)
- Table 17. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sale Price by Application (2018-2023) & (US\$/Unit)
- Table 18. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Company (2018-2023) & (K Units)
- Table 19. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Company (2018-2023)
- Table 20. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Company (2018-2023) (\$ Millions)

Table 21. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Company (2018-2023)

Table 22. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sale Price by Company (2018-2023) & (US\$/Unit)

Table 23. Key Manufacturers Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Producing Area Distribution and Sales Area

Table 24. Players Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Products Offered

Table 25. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 26. New Products and Potential Entrants

Table 27. Mergers & Acquisitions, Expansion

Table 28. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Geographic Region (2018-2023) & (K Units)

Table 29. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share Geographic Region (2018-2023)

Table 30. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 31. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Geographic Region (2018-2023)

Table 32. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country/Region (2018-2023) & (K Units)

Table 33. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country/Region (2018-2023)

Table 34. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country/Region (2018-2023) & (\$ millions)

Table 35. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country/Region (2018-2023)

Table 36. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2018-2023) & (K Units)

Table 37. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2018-2023)

Table 38. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2018-2023) & (\$ Millions)

Table 39. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country (2018-2023)

Table 40. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2018-2023) & (K Units)

Table 41. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales by Application (2018-2023) & (K Units)

Table 42. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales by Region (2018-2023) & (K Units)

Table 43. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales Market Share by Region (2018-2023)

Table 44. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Revenue by Region (2018-2023) & (\$ Millions)

Table 45. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Revenue Market Share by Region (2018-2023)

Table 46. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales by Type (2018-2023) & (K Units)

Table 47. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales by Application (2018-2023) & (K Units)

Table 48. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales by Country (2018-2023) & (K Units)

Table 49. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales Market Share by Country (2018-2023)

Table 50. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Revenue by Country (2018-2023) & (\$ Millions)

Table 51. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Revenue Market Share by Country (2018-2023)

Table 52. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales by Type (2018-2023) & (K Units)

Table 53. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Sales by Application (2018-2023) & (K Units)

Table 54. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Country (2018-2023) & (K Units)

Table 55. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country (2018-2023)

Table 56. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue by Country (2018-2023) & (\$ Millions)

Table 57. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country (2018-2023)

Table 58. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Type (2018-2023) & (K Units)

Table 59. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Application (2018-2023) & (K Units)

Table 60. Key Market Drivers & Growth Opportunities of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Table 61. Key Market Challenges & Risks of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Table 62. Key Industry Trends of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Table 63. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Raw Material

Table 64. Key Suppliers of Raw Materials

Table 65. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Distributors List

Table 66. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Customer List

Table 67. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Region (2024-2029) & (K Units)

Table 68. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 69. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2024-2029) & (K Units)

Table 70. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 71. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Region (2024-2029) & (K Units)

Table 72. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 73. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2024-2029) & (K Units)

Table 74. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 75. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Country (2024-2029) & (K Units)

Table 76. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 77. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Type (2024-2029) & (K Units)

Table 78. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 79. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Forecast by Application (2024-2029) & (K Units)

Table 80. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 81. Boya-Bio Basic Information, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 82. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications

Table 83. Boya-Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 84. Boya-Bio Main Business

Table 85. Boya-Bio Latest Developments

Table 86. Beijing Tiantan Biological Products Basic Information, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 87. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications

Table 88. Beijing Tiantan Biological Products Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 89. Beijing Tiantan Biological Products Main Business

Table 90. Beijing Tiantan Biological Products Latest Developments

Table 91. Hualan Bio Basic Information, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 92. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications

Table 93. Hualan Bio Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 94. Hualan Bio Main Business

Table 95. Hualan Bio Latest Developments

Table 96. Guangdong Shuagnlin Bio-pharmacy Basic Information, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 97. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications

Table 98. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 99. Guangdong Shuagnlin Bio-pharmacy Main Business

Table 100. Guangdong Shuagnlin Bio-pharmacy Latest Developments

Table 101. Weiguang Biological Basic Information, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 102. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications

Table 103. Weiguang Biological Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 104. Weiguang Biological Main Business

Table 105. Weiguang Biological Latest Developments

Table 106. Sinopharm Basic Information, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 107. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications

Table 108. Sinopharm Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 109. Sinopharm Main Business

Table 110. Sinopharm Latest Developments

Table 111. Shanghai RAAS Basic Information, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 112. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications

Table 113. Shanghai RAAS Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 114. Shanghai RAAS Main Business

Table 115. Shanghai RAAS Latest Developments

Table 116. CTBB Basic Information, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 117. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications

Table 118. CTBB Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 119. CTBB Main Business

Table 120. CTBB Latest Developments

Table 121. Nanyue Biopharming Basic Information, Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Manufacturing Base, Sales Area and Its Competitors

Table 122. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Product Portfolios and Specifications

Table 123. Nanyue Biopharming Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin

(2018-2023)

Table 124. Nanyue Biopharming Main Business

Table 125. Nanyue Biopharming Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Figure 2. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Report Years Considered

Figure 3. Research Objectives

Figure 4. Research Methodology

Figure 5. Research Process and Data Source

Figure 6. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Growth Rate 2018-2029 (K Units)

Figure 7. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth Rate 2018-2029 (\$ Millions)

Figure 8. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales by Region (2018, 2022 & 2029) & (\$ Millions)

Figure 9. Product Picture of 1g/20ml

Figure 10. Product Picture of 1.25g/25ml

Figure 11. Product Picture of 2.5g/50ml

Figure 12. Product Picture of 5g/100ml

Figure 13. Product Picture of 10g/200ml

Figure 14. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type in 2022

Figure 15. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Type (2018-2023)

Figure 16. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Consumed in Hospital

Figure 17. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market: Hospital (2018-2023) & (K Units)

Figure 18. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Consumed in Clinic

Figure 19. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market: Clinic (2018-2023) & (K Units)

Figure 20. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Consumed in Others

Figure 21. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market: Others (2018-2023) & (K Units)

Figure 22. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2022)

Figure 23. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Application in 2022

Figure 24. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market by Company in 2022 (K Units)

Figure 25. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Company in 2022

Figure 26. Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market by Company in 2022 (\$ Million)

Figure 27. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Company in 2022

Figure 28. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Geographic Region (2018-2023)

Figure 29. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Geographic Region in 2022

Figure 30. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales 2018-2023 (K Units)

Figure 31. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue 2018-2023 (\$ Millions)

Figure 32. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales 2018-2023 (K Units)

Figure 33. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue 2018-2023 (\$ Millions)

Figure 34. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales 2018-2023 (K Units)

Figure 35. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue 2018-2023 (\$ Millions)

Figure 36. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales 2018-2023 (K Units)

Figure 37. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue 2018-2023 (\$ Millions)

Figure 38. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country in 2022

Figure 39. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country in 2022

Figure 40. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2018-2023)

Figure 41. Americas Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2018-2023)

Figure 42. United States Human Immunoglobulin (pH4) for Intravenous Injection

(COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 43. Canada Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 44. Mexico Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 45. Brazil Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 46. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Region in 2022

Figure 47. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Regions in 2022

Figure 48. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2018-2023)

Figure 49. APAC Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2018-2023)

Figure 50. China Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 51. Japan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 52. South Korea Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 53. Southeast Asia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 54. India Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 55. Australia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 56. China Taiwan Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 57. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country in 2022

Figure 58. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country in 2022

Figure 59. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2018-2023)

Figure 60. Europe Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2018-2023)

Figure 61. Germany Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 62. France Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 63. UK Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 64. Italy Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 65. Russia Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 66. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Country in 2022

Figure 67. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share by Country in 2022

Figure 68. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Type (2018-2023)

Figure 69. Middle East & Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share by Application (2018-2023)

Figure 70. Egypt Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 71. South Africa Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Israel Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 73. Turkey Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 74. GCC Country Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Growth 2018-2023 (\$ Millions)

Figure 75. Manufacturing Cost Structure Analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) in 2022

Figure 76. Manufacturing Process Analysis of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Figure 77. Industry Chain Structure of Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)

Figure 78. Channels of Distribution

Figure 79. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Forecast by Region (2024-2029)

Figure 80. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Revenue Market Share Forecast by Region (2024-2029)

Figure 81. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Sales Market Share Forecast by Type (2024-2029)

Figure 82. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)
Revenue Market Share Forecast by Type (2024-2029)

Figure 83. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)
Sales Market Share Forecast by Application (2024-2029)

Figure 84. Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19)
Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/G97A0D9BDED2EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G97A0D9BDED2EN.html>